

Special Issue

Geriatric Oncology: From Research to Clinical Practice

Message from the Guest Editor

The number of older patients with cancer is strongly increasing. Despite the fact that around 50% of new cancer cases occur in older adults, these patients are strongly underrepresented in randomized clinical trials, resulting in a poor evidence base for oncological treatments in older patients. Treatment of the heterogeneous older population can be complicated by ageing-related factors such as functional decline, cognitive impairments, comorbidity, and polypharmacy. This makes it essential to study this population in detail, and to measure ageing-related factors in clinical studies by using geriatric assessments. This Special Issue focuses on studies specifically targeting older adults with cancer. We invite clinical studies and implementation studies as well as basic and translational research in older patients with cancer. We are especially interested in studies that focus on further individualizing treatments, such as geriatric assessment studies and biomarker studies, as well as studies focusing on patient-related outcome measures such as quality of life and functional or cognitive outcomes of treatment.

Guest Editor

Dr. Nienke de Glas

Department of Medical Oncology, Leiden University Medical Center (LUMC), Leiden, The Netherlands

Deadline for manuscript submissions

closed (30 May 2021)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/60493

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)